# Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies

> **NIH NIH U01** · UNIVERSITY OF PENNSYLVANIA · 2022 · $311,482

## Abstract

Statement of Work
Specific activities overseen by the Brunden laboratory include: 1) testing of prodrugs in established
HEK293 and neuron microtubule stabilization assays; 2) intravenous and oral pharmacokinetic testing of
prodrugs to determine the rate of conversion of prodrugs to the desired active compound; 3) assessment of
preferred prodrugs for pharmacodynamic effect in wild-type mice to establish the minimum effective
dose and duration of compound effect; and 4) determination of preferred prodrug acute maximum
tolerated dose and the no adverse effect dose after 3 weeks of dosing.

## Key facts

- **NIH application ID:** 10553899
- **Project number:** 3U01AG061173-04S1
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** KURT R. BRUNDEN
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $311,482
- **Award type:** 3
- **Project period:** 2019-03-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10553899

## Citation

> US National Institutes of Health, RePORTER application 10553899, Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies (3U01AG061173-04S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10553899. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*